How have the results of ODYSSEY Outcomes—especially as they relate to progressive CV risk reductions in patients with high LDL-C levels who achieve target levels of 50 mg/dL or less—support the “treat-to-target” approach to lipid management?

How have the results of ODYSSEY Outcomes—especially as they relate to progressive CV risk reductions in patients with high LDL-C levels who achieve target levels of 50 mg/dL or less—support the “treat-to-target” approach to lipid management?

How have the results of ODYSSEY Outcomes—especially as they relate to progressive CV risk reductions in patients with high LDL-C levels who achieve target levels of 50 mg/dL or less—support the “treat-to-target” approach to lipid management?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Freek W A Verheugt, MD, PhD

Freek W A Verheugt, MD, PhD

Professor of Cardiology Chairman of the Department of Cardiology Heartcenter of the University Medical Center Nijmegen, The Netherlands